Oppenheimer & Co. Inc. Cuts Stock Holdings in Capricor Therapeutics, Inc. $CAPR

Key Points

• Oppenheimer trimmed its stake in Capricor by 40.3% in Q4, selling 54,600 shares and ending the period with 80,813 shares worth about $2.33 million.
• Significant insider selling occurred on March 31—Director Karimah Es Sabar sold 61,265 shares and CFO Anthony Bergmann sold 25,000—and insiders have sold a total of 172,529 shares valued at $5.3 million over the past 90 days (insiders own 9.2%).
• Wall Street sentiment is largely positive: nine analysts rate CAPR as a Buy versus one Sell, several firms raised price targets (B. Riley to $63, Cantor $62, HC Wainwright $60, Piper $58), and the average analyst price target is $46.09.

Oppenheimer & Co. Inc. trimmed its position in shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) by 40.3% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 80,813 shares of the biotechnology company's stock after selling 54,600 shares during the quarter. Oppenheimer & Co. Inc. owned about 0.18% of Capricor Therapeutics worth $2,332,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the company. GoalVest Advisory LLC purchased a new stake in shares of Capricor Therapeutics during the fourth quarter valued at about $59,000. Russell Investments Group Ltd. lifted its position in shares of Capricor Therapeutics by 122.2% during the third quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company's stock valued at $37,000 after buying an additional 2,786 shares during the last quarter. Legal & General Group Plc lifted its position in shares of Capricor Therapeutics by 8.4% during the second quarter. Legal & General Group Plc now owns 41,273 shares of the biotechnology company's stock valued at $410,000 after buying an additional 3,205 shares during the last quarter. Rhumbline Advisers lifted its position in shares of Capricor Therapeutics by 7.3% during the second quarter. Rhumbline Advisers now owns 53,450 shares of the biotechnology company's stock valued at $531,000 after buying an additional 3,636 shares during the last quarter. Finally, Farther Finance Advisors LLC purchased a new stake in shares of Capricor Therapeutics during the third quarter valued at about $28,000. 21.68% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Capricor Therapeutics

In related news, Director Karimah Es Sabar sold 61,265 shares of the stock in a transaction that occurred on Tuesday, March 31st. The shares were sold at an average price of $30.17, for a total value of $1,848,365.05. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Anthony Bergmann sold 25,000 shares of the stock in a transaction that occurred on Tuesday, March 31st. The shares were sold at an average price of $30.13, for a total transaction of $753,250.00. Following the completion of the transaction, the chief financial officer directly owned 8,223 shares of the company's stock, valued at $247,758.99. The trade was a 75.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 172,529 shares of company stock valued at $5,302,440 over the last ninety days. 9.20% of the stock is currently owned by insiders.

Capricor Therapeutics Stock Up 8.4%

Shares of Capricor Therapeutics stock opened at $33.50 on Tuesday. The firm has a market capitalization of $1.94 billion, a P/E ratio of -14.82 and a beta of 0.48. The company has a 50 day moving average price of $31.11 and a 200 day moving average price of $22.76. Capricor Therapeutics, Inc. has a 52 week low of $4.30 and a 52 week high of $40.37.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last announced its quarterly earnings data on Thursday, March 12th. The biotechnology company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.11). As a group, research analysts anticipate that Capricor Therapeutics, Inc. will post 0.01 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have commented on CAPR. B. Riley Financial increased their price target on shares of Capricor Therapeutics from $50.00 to $63.00 and gave the company a "buy" rating in a research report on Friday, March 13th. Cantor Fitzgerald set a $62.00 price target on shares of Capricor Therapeutics and gave the company an "overweight" rating in a research report on Friday, March 13th. HC Wainwright reissued a "buy" rating and set a $60.00 price target on shares of Capricor Therapeutics in a research report on Tuesday, March 10th. Wall Street Zen lowered shares of Capricor Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday, January 11th. Finally, Piper Sandler reissued an "overweight" rating and set a $58.00 price target (up from $45.00) on shares of Capricor Therapeutics in a research report on Friday, March 13th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $46.09.

Capricor Therapeutics Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company's leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.

Want to see what other hedge funds are holding CAPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.